NCT05036512 - A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

November 2, 2022

Study Completion Date

February 7, 2023

Conditions

Sickle Cell Disease

Interventions

DRUG

GBT021601

Administered orally with water as a single dose in the morning.

Trial Locations (4)

Oxford Compounding, North Perth

Harry Perkins Institute of Medical Research, Nedlands

Linear Clinical Research, Nedlands

ICON Early Phase Services, LLC, San Antonio